Fit for Purpose: Clinical Validation

Agilent pharmDx assays help guide selection of the right patients to the intended treatment. Agilent partners with pharma early-on in the drug development process, which allows the assays to be clinically validated for a specific cancer therapy, on a specific platform, for a specific cancer indication and with a specific scoring algorithm. In the video, Monika Polewski, Clinical Development Manager at Agilent Technologies, explains the process of clinically validating a pharmDx assay.

The video covers various central points about Clinical Validation including:  

• Purpose and Scope of Clinical Validation
• Integration with Drug Development
• Evaluation Criteria and Methods
• Regulatory and Diagnostic Implications

This website addresses general principles for CDx scoring and is for education purposes only. Not all cancer indications mentioned are approved worldwide. Please refer to local Instructions for Use for further details.D0140429_1.00